TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38721015
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by liver transplantation (LT)
Study: 38721358
Drug: Selumetinib 25
Normalized name: selumetinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib 25 mg/m administered with a low-fat meal
Study: 38721358
Drug: Selumetinib 25
Normalized name: selumetinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib 25 mg/m administered in a fasted state
Study: 38721402
Drug: Lacnotuzumab (MCS110)
Normalized name: dalotuzumab
DrugBank: Lacnotuzumab (DB14928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacnotuzumab (MCS110) in combination with Spartalizumab (PDR001)
Study: 38721680
Drug: Oral preparation
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral preparation of hyaluronic acid, chondroitin sulfate, N-acetylglucosamine, and vitamin C once a day for 3 months
Study: 38721680
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received an oral preparation of cranberry, D-mannose, propolis extract, turmeric, and Boswellia twice a day for 3 months
Study: 38721977
Drug: Automated vertebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated vertebral segmentation for low dose CT
Study: 38721977
Drug: Fracture assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fracture assessment from low dose CT
Study: 38722621
Drug: Ponatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib (30 mg/d) with reduced-intensity chemotherapy, followed by single-agent ponatinib after cycle 20.
Study: 38722621
Drug: Imatinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (600 mg/d) with reduced-intensity chemotherapy, followed by single-agent imatinib after cycle 20.
Study: 38722621
Drug: Ponatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib (30 mg/d)
Study: 38722621
Drug: Imatinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (600 mg/d)
Study: 38722641
Drug: Nivolumab induction
Normalized name: nivolumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab induction (240 mg every 2 weeks)
Study: 38722641
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + ipilimumab (3 mg/kg + 1 mg/kg, followed by 1 mg/kg + 3 mg/kg)
Study: 38722641
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + ipilimumab (1 mg/kg + 3 mg/kg)
Study: 38722641
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + ipilimumab (high-dose)
Study: 38722664
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (InO) at 0.6 mg/m2 on day 8 and day 15 of a 28-day cycle combined with DA-EPOCH
Study: 38722831
Drug: Sit Less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sit Less program (12-week intervention including goal-setting session, Fitbit, smart water bottle, weekly text messages)
Study: 38722926
Drug: Mindfulness and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness and acceptance-based intervention (weekly 90-minute group sessions for four consecutive weeks)
Study: 38723189
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist protocol with individualized fixed daily dose of follitropin delta
Study: 38723189
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol with individualized fixed daily dose of follitropin delta
Study: 38723227
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + relatlimab + chemotherapy
Study: 38723227
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + chemotherapy
Study: 38723373
Drug: encorafenib 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: encorafenib 450 mg QD plus binimetinib 45 mg BID
Study: 38723373
Drug: vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib 960 mg BID
Study: 38723373
Drug: encorafenib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: encorafenib monotherapy 300 mg QD
Study: 38723644
Drug: Maralixibat (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat (starting dose 142.5 μg/kg, then escalated to 570 μg/kg)
Study: 38724058
Drug: Intravenous injections
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of ICG twice with intraoperative assessment of anastomotic blood flow using the near-infrared NIR-ICG system during total mesorectal excision (TME) surgery.
Study: 38724293
Drug: felcisetrag 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: felcisetrag 0.5 mg daily
Study: 38724293
Drug: felcisetrag 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: felcisetrag 0.5 mg pre-surgery
Study: 38724531
Drug: Prior treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior treatment with second-line drugs
Study: 38724605
Drug: Delayed fortification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed fortification at 80 ml/kg/day
Study: 38724874
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment (AHT) targeting systolic blood pressure (SBP) ≤140 mmHg for a median duration of 7 weeks
Study: 38724874
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment (AHT)
Study: 38724991
Drug: Molecularly guided
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly guided treatment (MGT) informed by molecular tumor boards (MTBs)
Study: 38724991
Drug: Tier 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tier 1: Therapeutic use of investigational drugs targeting genetic alterations (e.g., ALK, EGFR, ERBB2, BRAF, FH, ROS1, RET)
Study: 38724991
Drug: Tier 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tier 2: Drugs with approved indications or permitted for treatment outside of approved indications
Study: 38725194
Drug: Intraovarian PRP
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraovarian PRP injection
Study: 38725258
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo D/C/F/TAF tablets
Study: 38725258
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo D/C/TAF tablets
Study: 38725995
Drug: High-dose encorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose encorafenib 300 mg BID plus binimetinib 45 mg BID
Study: 38725995
Drug: Standard-dose encorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose encorafenib 450 mg QD plus binimetinib 45 mg BID
Study: 38725995
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose encorafenib 600 mg QD plus binimetinib 45 mg BID
Study: 38726365
Drug: Batiraxcept in
Normalized name: Batiraxcept
DrugBank: Batiraxcept (DB17522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batiraxcept in combination with durvalumab
Study: 38727837
Drug: Camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (200 mg once every 3 weeks via intravenous infusion) plus famitinib (20 mg once daily)
Study: 38728033
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure self-monitoring plus medication self-titration
Study: 38728603
Drug: Patients taking
Normalized name: Lamictal Blue (For Patients Taking Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients taking treatment for substance use disorder
Study: 38728925
Drug: Heparin-mediated extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-mediated extracorporeal LDL-precipitation (HELP)-apheresis
Study: 38729196
Drug: MVA-NP+M1 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-NP+M1 (0.5 mL intramuscular injections of modified vaccinia Ankara expressing H3N2 nucleoprotein and matrix protein 1)
Study: 38729399
Drug: Cotadutide 600
Normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotadutide 600 μg
Study: 38729426
Drug: Subcutaneous atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous atezolizumab (1875 mg)
Study: 38729426
Drug: Intravenous atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous atezolizumab (1200 mg)
Study: 38729636
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual therapy without spironolactone)
Study: 39297052
Drug: Rozanolixizumab 10
Normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozanolixizumab 10 mg/kg
Study: 38729748
Drug: Erythropoietin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (500 U/kg daily) for 9 days
Study: 38729748
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham injections)
Study: 38729754
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with reconstructive lymphatic surgery
Study: 38729754
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment alone (control group)
Study: 38729756
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (no cerclage)
Study: 38729951
Drug: Fosfomycin, flomoxef,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin, flomoxef, and amikacin (combination regimens)
Study: 38730030
Drug: Guided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-delivered psychodynamic therapy (IPDT)
Study: 38730030
Drug: Unguided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided internet-delivered psychodynamic therapy (IPDT)
Study: 38730030
Drug: Guided and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided and unguided internet-delivered psychodynamic therapy (IPDT)
Study: 38730089
Drug: Urosepsis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urosepsis with multi-drug-resistant (MDR) pathogens
Study: 38730096
Drug: Perampanel (monotherapy)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel (monotherapy)
Study: 38730096
Drug: Perampanel (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (first adjunctive therapy)
Study: 38730343
Drug: Serological multiplex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serological multiplex assays based on various antigen targets and antibody properties.
Study: 38730496
Drug: lecanemab 10
Normalized name: LECANEMAB 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [LEQEMBI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: lecanemab 10 mg/kg biweekly
Study: 38730548
Drug: Liver-directed radiotherapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver-directed radiotherapy with escalating functional liver radiation dose constraints (prescription dose 67.5-75 Gy in 15 fractions or 75-100 Gy in 25 fractions)
Study: 38733160
Drug: Sacubitril/valsartan (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (titrated to the maximum dose of 97/103 mg twice daily)
Study: 38733340
Drug: Azathioprine 150
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine 150 mg/day and hydroxyurea 25 mg/kg/day for 3 months prior to alemtuzumab 1 mg/kg and 300 cGy TBI conditioning
Study: 38734016
Drug: Doravirine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine (100 mg) and Islatravir (0·75 mg)
Study: 38734383
Drug: Bulevirtide 2
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Bulevirtide 2 mg/day for 144 weeks
Study: 38734383
Drug: Bulevirtide 10
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Bulevirtide 10 mg/day for 144 weeks
Study: 38734383
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment for 48 weeks followed by Bulevirtide 10 mg/day for 96 weeks
Study: 38734495
Drug: S-268019-b (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-268019-b (10 µg, 2 doses, 28 days apart)
Study: 38735220
Drug: SC trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC trastuzumab (fixed dose 600 mg, q3w) administered through a hand-held syringe followed by 7 cycles of SC trastuzumab administered with an SID
Study: 38736116
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg subcutaneously every 4 weeks
Study: 38737002
Drug: Once-weekly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous semaglutide 1.0 mg
Study: 38737110
Drug: Lower PHR
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower PHR (PHR-L) with DM
Study: 38737349
Drug: Transcranial photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial photobiomodulation (tPBM) - Pulses of near-infrared light (40 Hz, 850 nm) delivered noninvasively twice a week for eight weeks
Study: 38737600
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion radiotherapy (CIRT) with RBE-weighted fraction doses of 8.1-10.5 Gy, total doses 32.4-42.0 Gy, performed every other day in four fractions
Study: 38737708
Drug: Sustained-release carvedilol
Normalized name: carvedilol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release carvedilol (carvedilol-SR)
Study: 38738598
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate 200 mg daily for 8 weeks
Study: 38739079
Drug: Aficamten (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten (starting dose 5 mg, maximum dose 20 mg)
Study: 38739123
Drug: High-intensity care
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity care (HIC) - rapid uptitration of heart failure GDMT to 100% of recommended doses within 2 weeks of discharge and 4 scheduled outpatient visits over 2 months after discharge
Study: 38739306
Drug: Back2School (B2S),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Back2School (B2S), a modular transdiagnostic cognitive behavioral therapy (CBT) for SAPs, with an average of 15.0 hours of intervention (SD=3.9) over three months.
Study: 38739306
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU), comprising public and/or private intervention services, with an average of 13.4 hours of intervention (SD=21.6).
Study: 38739382
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (micronized microencapsulated ferric pyrophosphate), 1 mg/kg, once daily from age 4 to 9 months.
Study: 38739382
Drug: Placebo (maltodextrin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin), once daily from age 4 to 9 months.
Study: 38739422
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of adalimumab-adbm
Study: 38739615
Drug: State-of-the-art periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: State-of-the-art periodontal treatment during pregnancy
Study: 38739615
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment after giving birth
Study: 38739766
Drug: Skin-nerve preparations
Normalized name: oryctolagus cuniculus nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-nerve preparations of contusion SCI mice 7 days after injury
Study: 38740027
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted lopinavir (lopinavir 400 mg twice daily + ritonavir 100 mg twice daily)
Study: 38740027
Drug: Raltegravir (raltegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (raltegravir 400 mg twice daily)
Study: 38740027
Drug: Triple nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple nucleoside reverse transcriptase inhibitor (NRTI) group (tenofovir 245 mg once daily + emtricitabine 200 mg once daily + zidovudine 250 mg twice daily)
Study: 38740030
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles
Study: 38740499
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (LDN) starting at 1 mg daily, up-titrated to 4.5 mg daily or maximum tolerated dose over 16 weeks.
Study: 38740499
Drug: Placebo starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo starting at 1 mg daily, up-titrated to 4.5 mg daily or maximum tolerated dose over 16 weeks.
Study: 38740532
Drug: High-intensity care
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity care (HIC) consisting of rapid up-titration of guideline-directed medical therapy (GDMT) and close follow-up
Study: 38741375
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with immune checkpoint inhibitors (ICIs)
Study: 38741607
Drug: rhPTH(1-84) 50
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH(1-84) 50 μg once daily, adjusted based on albumin-corrected serum calcium levels
Study: 38741607
Drug: rhPTH(1-84) 50
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH(1-84) 50 μg once daily
Study: 38743075
Drug: Intra-operative injection
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative injection of bupivacaine into the obturator membrane
Study: 38743248
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment for periodontitis
Study: 38743265
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 8 weekly sessions
Study: 38743265
Drug: Whole-Body Hyperthermia
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-Body Hyperthermia (WBH) - 8 weekly sessions
Study: 38743265
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH) combined
Study: 38743716
Drug: Prison treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prison treatment as usual (Control)
Study: 38743958
Drug: Gestational age-based
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestational age-based dosing of UFH (5,000 units subcutaneously every 12 hours in first trimester; 7,500 units in second trimester; 10,000 units in third trimester)
Study: 38743958
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of UFH (5,000 units subcutaneously every 12 hours)
Study: 38743958
Drug: Gestational age-based
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestational age-based dosing of UFH
Study: 38743958
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of UFH
Study: 38744144
Drug: Quizartinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quizartinib (30 mg, 40 mg, or 60 mg) in combination with azacitidine
Study: 38744460
Drug: First Disease-Modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Disease-Modifying Therapy (DMT)
Study: 38744844
Drug: ARCT-154 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARCT-154 vaccine (two doses, 28 days apart)
Study: 38744844
Drug: ARCT-154 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARCT-154 vaccine
Study: 38745011
Drug: PR006 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PR006 gene therapy
Study: 38745158
Drug: Concentrated transdiagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated transdiagnostic and micro choice-based group treatment
Study: 38745322
Drug: Video Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video Therapy (VT)
Study: 38745333
Drug: Preoperative hypofractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative hypofractionated proton beam therapy (PBT) - 30 Gy radiobiological equivalent in 5 fractions delivered every other day.
Study: 38745983
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of indocyanine green (ICG) fluorescence imaging
Study: 38746205
Drug: TELESCOPE intervention:
Approvals — FDA: no, EMA: no, PMDA: no
Description: TELESCOPE intervention: telehealth decision coaching session about LCS delivered by trained patient navigators, with a low-dose CT scan (LDCT) order placed for each patient wanting LCS.
Study: 38746220
Drug: Ribociclib 800mg
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib 800mg daily plus Gemcitabine 1000mg/m2
Study: 38747162
Drug: NBO-2h group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBO-2h group (10 L/min for 2 hours)
Study: 38747162
Drug: NBO-4h group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBO-4h group (10 L/min for 4 hours)
Study: 38747162
Drug: NBO-6h group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBO-6h group (10 L/min for 6 hours)